New York, NY – The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Developing Biological Markers to Improve Clinical Care in Autism” on Tuesday, February 13, 2024, at 2:00 pm ET. The presenter will be James McPartland, Ph.D., Harris Professor of Child Psychiatry and Psychology at Yale School...
Latest News
Matsuyama, Japan – Multiple myeloma still appears to be an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment. Immunotherapy is an attractive strategy to target myeloma cells with drug resistance. The next-generation modality which can safely and effectively...
BOSTON, Mass. — Dewpoint Therapeutics Inc., a biotechnology company that translates the novel science of condensates into breakthrough therapeutics, today announced the filing of multiple patent applications covering novel compounds and their use in the potential treatment of amyotrophic lateral sclerosis (ALS). Composition of matter covered by these applications aims...
In patients with amyotrophic lateral sclerosis (ALS), treatment with dextromethorphan/quinidine (DM/Q) was not shown to prevent failure of noninvasive respiratory management and had no effect on long-term deterioration of bulbar function, according to the results of a prospective, case-cohort study published in Respiratory Medicine. Investigators sought to evaluate whether treatment with...
A drug currently FDA-approved for use in diabetes shows some protective effects in the brains of patients with relapsing remitting multiple sclerosis, researchers at the University of Illinois at Chicago College of Medicine report in a study currently available online in the Journal of Neuroimmunology. In a small, double-blinded clinical...
TARRYTOWN, N.Y. — Today, Diabetic Tussin, the trusted cough syrup brand for people with diabetes and prediabetes, announces its sugar-free cold and cough solution is back on shelves. This restock brings with it the Better Choices for Life mark from the American Diabetes Association® (ADA). This over-the-counter cold and cough...
Differentiation syndrome (DS), also termed retinoic acid syndrome or all-trans retinoic acid (ATRA) syndrome, is a recognized complication in patients undergoing treatment with newer targeted therapies for acute myeloid leukemia (AML), such as FLT3 and IDH inhibitors.¹ Evidence suggests the syndrome results from a severe systemic inflammatory response induced by...
PARIS, France – The time from symptom onset to receiving a diagnosis of Gaucher disease has significantly decreased over the last decades, from a median of 5.4 years before 2000 to less than one year after 2020, a study in France has found. Still, researchers noted that, while most patients received...
WATERTOWN, Mass. — Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying cause of intractable genetic diseases, today announced the publication of study results detailing new health economics and outcomes research (HEOR) that characterizes the significant healthcare utilization and costs associated with hereditary...
DIAG723 is supported by a groundbreaking preclinical profile demonstrating its disease-modifying potential WATERTOWN, Mass. — Diagonal Therapeutics, a biotechnology company focused on correcting dysregulated signaling with clustering antibodies that address the underlying cause of intractable genetic diseases, today announced that both the U.S. Food and Drug Administration (FDA) granted orphan drug...